iCAD, Inc. (NASDAQ:ICAD) Sees Large Decrease in Short Interest

iCAD, Inc. (NASDAQ:ICAD) was the target of a significant decline in short interest during the month of February. As of February 28th, there was short interest totalling 231,100 shares, a decline of 23.1% from the February 13th total of 300,600 shares. Currently, 0.9% of the shares of the stock are sold short. Based on an average daily trading volume, of 444,700 shares, the days-to-cover ratio is presently 0.5 days.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised iCAD from a “sell” rating to a “hold” rating in a report on Thursday, February 20th.

iCAD Stock Performance

Shares of ICAD stock remained flat at $2.29 on Monday. The stock had a trading volume of 109,813 shares, compared to its average volume of 247,489. The firm has a market capitalization of $60.78 million, a PE ratio of -17.65 and a beta of 1.95. The stock’s 50 day simple moving average is $2.62 and its 200-day simple moving average is $2.04. iCAD has a one year low of $1.18 and a one year high of $3.78.

Institutional Trading of iCAD

A number of institutional investors and hedge funds have recently modified their holdings of ICAD. waypoint wealth counsel increased its stake in iCAD by 44.0% during the 4th quarter. waypoint wealth counsel now owns 14,400 shares of the technology company’s stock worth $26,000 after purchasing an additional 4,400 shares in the last quarter. Thompson Davis & CO. Inc. bought a new position in shares of iCAD in the fourth quarter valued at $31,000. PKS Advisory Services LLC bought a new position in shares of iCAD in the fourth quarter valued at $53,000. Wells Fargo & Company MN grew its stake in shares of iCAD by 51.3% in the fourth quarter. Wells Fargo & Company MN now owns 39,542 shares of the technology company’s stock valued at $72,000 after buying an additional 13,402 shares in the last quarter. Finally, Integrated Wealth Concepts LLC bought a new position in shares of iCAD in the fourth quarter valued at $92,000. 24.61% of the stock is owned by institutional investors.

About iCAD

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.